Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 231 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Center M Clear all
Active, not recruiting Phase 2 Interventional Results available

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02179086
View directory record Official record
Conditions
Glioblastoma
Interventions
Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
230
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

NCT05032820
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, bb2121, Cyclophosphamide, Fludarabine, leukapheresis
Drug · Biological · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional Results available

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT00862134
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PR104, docetaxel, Granulocyte colony-stimulating factor
Drug
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 5, 2026, 7:35 PM EDT
Not yet recruiting Not applicable Interventional

Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)

NCT07756398
View directory record Official record
Conditions
Valvular Heart Disease Patients, Aortic Stenosis, Mitral Regurgitation, Left Ventricular Diastolic Dysfunction
Interventions
Kosmos Torso-One AI-guided Point-of-Care Ultrasound (EchoNous, Inc.)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 5, 2026, 7:35 PM EDT
Active, not recruiting Phase 1 Interventional

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

NCT03672318
View directory record Official record
Conditions
Multiple Myeloma, Immune System Diseases
Interventions
CAR138 T Cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2039
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 1 Interventional

Metformin in Children With Relapsed or Refractory Solid Tumors

NCT01528046
View directory record Official record
Conditions
Solid Tumors, Primary Brain Tumors
Interventions
Vincristine, Irinotecan, Temozolomide, Metformin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Hartford, Connecticut • Wilmington, Delaware • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 5, 2026, 7:35 PM EDT
Active, not recruiting Phase 2 Interventional

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

NCT04978584
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Tafasitamab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 1Phase 2 Interventional

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

NCT04210037
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
APG-1252, Paclitaxel
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

NCT01754116
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Center M: Digital Health Innovation Pilot

NCT06000449
View directory record Official record
Conditions
Perinatal Depression
Interventions
Center M, Treatment as Usual
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 5, 2026, 7:35 PM EDT
Recruiting Phase 1 Interventional

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

NCT04190862
View directory record Official record
Conditions
Anal Fistula
Interventions
E-CEL UVEC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

NCT03504410
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
CPI-613 + High Dose Cytarabine and Mitoxantrone, High Dose Cytarabine and Mitoxantrone, Mitoxantrone, Etoposide and Cytarabine, Fludarabine, Cytarabine, Filgrastim
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Scottsdale, Arizona • Orange, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Systemic Lupus Erythematosus

NCT00383513
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

NCT00322218
View directory record Official record
Conditions
Lymphoma, Large Cell, Diffuse
Interventions
Zevalin
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

NCT00963872
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
cyclophosphamide, fludarabine phosphate, Total body irradiation, Umbilical cord blood unit with C3a fragment, Unmanipulated UCB Unit
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TBI Dose De-escalation for Fanconi Anemia

NCT00352976
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone Marrow Transplantation, Mycophenolate Mofetil, Sirolimus
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

NCT00931918
View directory record Official record
Conditions
Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
70
States / cities
Beverly Hills, California • Fountain Valley, California • Fullerton, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 5, 2026, 7:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a Life Coaching Seminar on Gratitude and Psychological Well-Being

NCT04172051
View directory record Official record
Conditions
Psychological, Depression, Anxiety, Psychological Stress, Mental Health Wellness 1, Mental Stress, Mental Depression
Interventions
Tony Robbins Date with Destiny
Behavioral
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Stanford, California • Tampa, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Sep 5, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

NCT00392782
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, fludarabine phosphate, thiotepa, peripheral blood stem cell transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 5, 2026, 7:35 PM EDT